PROS1 and COVID-19: Since convalescent plasma from SARS-CoV patients showed a modest inhibition of SARS-CoV-2 entry [186], neutralizing monoclonal antibodies specifically developed against SARS-CoV-2 S protein could be effective in neutralizing SAR-CoV-2 infections and treating COVID-19 patients.